PCVX

Vaxcyte Inc

Add to Watchlist

Advanced Chart

45.280

+0.53(1.184%)1D

Line

Candle

YTD

High

45.360

Open

44.300

VWAP

44.58

Vol

1.39M

Mkt Cap

5.88B

Low

43.780

Amount

62.19M

EV/EBITDA(TTM)

Total Shares

108.80M

4.22B

EV/OCF(TTM)

P/S(TTM)

Vaxcyte Inc. is a clinical-stage vaccine innovation company. The Company is engaged in developing spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its pipeline includes VAX-31, a 31-valent PCV candidate advancing to a Phase III adult clinical program and being evaluated in a Phase II infant clinical program, which is being developed for the prevention of invasive pneumococcal disease (IPD) in adults and infants and is the broadest-spectrum pneumococcal conjugate vaccine (PCV) candidate in the clinic. VAX-24, the Company’s 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market and is being evaluated in a Phase II infant study. Its pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease; and VAX-GI, a vaccine candidate designed to prevent Shigella.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q4

FY2026Q1

-1.310

+57.83%

-1.381

+35.42%

-1.617

+55.45%

Estimates Revision

Stock Price

Go Up

+34.28%

In Past 3 Month

8 Analyst Rating

113.27% Upside

Wall Street analysts forecast PCVX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PCVX is 96.57 USD with a low forecast of 38.00 USD and a high forecast of 163.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Buy

1 Hold

0 Sell

Strong Buy

113.27% Upside

Current: 45.280

Low

38.00

Averages

96.57

High

163.00

113.27% Upside

Current: 45.280

Low

38.00

Averages

96.57

High

163.00

BTIG

Thomas Shrader

Buy

downgrade

$160 -> $85

2025-10-16

Reason

BTIG

Thomas Shrader

Price Target

$160 -> $85

2025-10-16

downgrade

Buy

Reason

BTIG analyst Thomas Shrader lowered the firm's price target on Vaxcyte to $85 from $160 and keeps a Buy rating on the shares. In a broader research note previewing Q3 results for select biotech names, the firm is updating its assumptions and models for the company, the analyst tells investors in a research note.

Goldman Sachs

Neutral

initiated

$38

2025-09-12

Reason

Goldman Sachs

Price Target

$38

2025-09-12

initiated

Neutral

Reason

Goldman Sachs initiated coverage of Vaxcyte with a Neutral rating and $38 price target. The firm believes the company's vaccine-focused platform provided "validating" data for its flagship pneumococcal conjugate vaccine franchise over the past three years, positioning Vaxcyte to be a leading player in the "large and established" pneumococcal vaccine market. However, an extended timeline to the company's next catalyst, the Phase 3 data in adults in late 2026, along with regulatory uncertainty related to vaccines will cap the stock's performance in the near term, the analyst tells investors in a research note.

TD Cowen

Tara Bancroft

Buy

downgrade

$85 -> $50

2025-08-07

Reason

TD Cowen

Tara Bancroft

Price Target

$85 -> $50

2025-08-07

downgrade

Buy

Reason

TD Cowen analyst Tara Bancroft lowered the firm's price target on Vaxcyte to $50 from $85 and keeps a Buy rating on the shares. The firm is confident that VAX-31 in adults should lead to robust immunogenicity and protection, resulting in a large market. In infants, though TD Cowen is heartened that the Phase II is moving forward with an optimized dose, this extends the data timeline to the first half of 2027. The firm remains confident in the success of the adult and infant programs.

Mizuho

Salim Syed

Outperform

maintain

2025-06-21

Reason

Mizuho

Salim Syed

Price Target

2025-06-21

maintain

Outperform

Reason

Cantor Fitzgerald

Carter Gould

Buy

Initiates

n/a

2025-04-22

Reason

Cantor Fitzgerald

Carter Gould

Price Target

n/a

2025-04-22

Initiates

Buy

Reason

Cantor Fitzgerald analyst Carter Gould initiated coverage of Vaxcyte with an Overweight rating.

Needham

Joseph Stringer

Strong Buy

Reiterates

$90

2025-04-08

Reason

Needham

Joseph Stringer

Price Target

$90

2025-04-08

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Vaxcyte Inc (PCVX.O) is -7.52, compared to its 5-year average forward P/E of -12.29. For a more detailed relative valuation and DCF analysis to assess Vaxcyte Inc 's fair value, click here.

Forward PE
Forward EV/EBITDA
Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-12.29

Current PE

-7.52

Overvalued PE

-8.03

Undervalued PE

-16.54

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-10.47

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

-5.52

Undervalued EV/EBITDA

-15.43

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

591.55

Current PS

45.28

Overvalued PS

1702.61

Undervalued PS

-519.51